Lineage Cell Therapeutics, Inc.
A clinical-stage biotechnology company developing "off-the-shelf" cell therapies for serious conditions, including spinal cord injuries and age-related macular degeneration. It began in 1990 as BioTime before rebranding in 2019 to its current name, which reflects how its platform steers stem cells along specific "lineages" to become particular cell types. Its programs include OPC1 for spinal cord repair and OpRegen for the eye disease dry AMD.
Common Share Purchase Warrants expiring October 1, 2018, exercise price .55
Bought 20.65M
Bought 9.19M · Sold 267.4K
Granted 44.7K
Granted 118.2K · Bought 364.5K · Sold 2.01M
Granted 1.58M · Bought 22.0K · Sold 270.0K
Granted 255.0K · Sold 72.1K
Granted 500.0K · Bought 5.4K · Sold 100.0K
Granted 219.0K · Bought 47.0K
Granted 50.0K · Sold 45.0K
Granted 781.1K · Bought 86.7K · Sold 450.0K
Granted 50.0K · Sold 36.0K
Bought 96.2K
Bought 75.0K
Bought 126.3K
Granted 109.8K · Bought 7.5K
Bought 97.5K
Granted 24.7K · Bought 50.0K · Sold 4.7K
Bought 35.0K
Granted 24.7K · Bought 10.0K · Sold 19.1K
Granted 41.3K · Bought 7.5K
Bought 32.0K
Granted 26.0K · Bought 15.0K
Bought 25.5K
Granted 33.8K · Bought 2.0K
Granted 105.0K · Sold 82.5K
Bought 5.0K
Bought 10.0K
Bought 10.0K
Granted 523.9K · Sold 539.3K
Bought 7.0K
Granted 6.0K · Sold 6.0K
Granted 74.0K · Sold 74.0K
Bought 5.0K
Bought 5.0K
Sold 43.9K
Bought 3.0K
Bought 500
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bradsher Neal C +2 co-filersDirector, 10% owner, 10% owner · 28 transactions | — | 99.21Mas of Jan 2025 | — | 20.65M | — |
| Bradsher Neal C +2 co-filersDirector, 10% owner, 10% owner · 57 transactions | — | 72.02Mas of Jun 2016 | — | 9.19M | 267.4K |
| Bradsher Neal CDirector, 10% owner · 2 transactions | — | 34.09Mas of Jun 2021 | 44.7K | — | — |
| Kingsley Alfred DDirector · 71 transactions | — | 6.85Mas of Feb 2023 | 118.2K | 364.5K | 2.01M |
| Karfunkel George10% owner · 2 transactions | — | 4.98Mas of May 2010 | — | — | — |
| Duberstein Gary K10% owner · 15 transactions | — | 4.67Mas of Aug 2010 | — | — | — |
| Greenbelt Corp /NYSee Remarks · 23 transactions | — | 1.04Mas of Dec 2017 | — | — | — |
| West Michael DCo-Chief Executive Officer, Director · 24 transactions | — | 893.9Kas of Sep 2018 | 1.58M | 22.0K | 270.0K |
| Segall JudithVice President & Secretary · 17 transactions | — | 591.2Kas of Apr 2016 | 255.0K | — | 72.1K |
| Greenway Partners L P10% owner · 8 transactions | — | 375.4Kas of Dec 2012 | — | — | — |
| Peabody RobertSr. VP, COO, and CFO · 5 transactions | — | 315.8Kas of Jul 2015 | 500.0K | 5.4K | 100.0K |
| Mulroy Michael H.Director · 4 transactions | — | 298.6Kas of Nov 2024 | 219.0K | 47.0K | — |
| Sternberg HalVice President, Director · 11 transactions | — | 259.3Kas of Feb 2010 | 50.0K | — | 45.0K |
| Culley Brian MPresident and CEO, Director · 46 transactions | — | 255.5K | 781.1K | 86.7K | 450.0K |
| Waitz Harold DVice President, Director · 11 transactions | — | 184.2Kas of Feb 2010 | 50.0K | — | 36.0K |
| Bailey Don MDirector · 1 transaction | — | 158.8Kas of Feb 2024 | — | 96.2K | — |
| Cartt Stephen LaHueDirector · 3 transactions | — | 155.1Kas of Aug 2015 | — | 75.0K | — |
| Lichtinger PedroDirector · 2 transactions | — | 126.3Kas of Jul 2014 | — | 126.3K | — |
| Mohanty Aditya P.Co-Chief Executive Officer, Director · 14 transactions | — | 101.4Kas of Jul 2018 | 109.8K | 7.5K | — |
| Farrell Stephen CDirector · 6 transactions | — | 97.5Kas of Jul 2018 | — | 97.5K | — |
| Russell Angus C.Director · 3 transactions | — | 92.2Kas of Jun 2021 | 24.7K | 50.0K | 4.7K |
| Amin DiptiDirector · 1 transaction | — | 35.0Kas of Mar 2022 | — | 35.0K | — |
| Andrews Deborah JDirector · 7 transactions | — | 34.7Kas of Jun 2021 | 24.7K | 10.0K | 19.1K |
| Patton Stephana EileneGeneral Counsel & Secretary · 5 transactions | — | 34.5Kas of Dec 2018 | 41.3K | 7.5K | — |
| Schlachet DavidDirector · 1 transaction | — | 32.0Kas of Jul 2017 | — | 32.0K | — |
| Samuel George A. IIIGeneral Counsel and Secretary · 11 transactions | — | 31.1K | 26.0K | 15.0K | — |
| Howe Jill AnnChief Financial Officer · 2 transactions | — | 25.5Kas of Nov 2024 | — | 25.5K | — |
| Skibsted RussellChief Financial Officer · 5 transactions | — | 24.1Kas of Dec 2018 | 33.8K | 2.0K | — |
| Seinberg Steven AChief Financial Officer · 12 transactions | — | 22.5Kas of Sep 2010 | 105.0K | — | 82.5K |
| Burns Arnold IDirector · 1 transaction | — | 15.0Kas of Jul 2012 | — | 5.0K | — |
| Cohen Abraham EDirector · 1 transaction | — | 10.0Kas of Jul 2012 | — | 10.0K | — |
| Jayasuriya AnulaDirector · 1 transaction | — | 10.0Kas of Dec 2023 | — | 10.0K | — |
| Hogge Gary S.SVP,Clinical & Medical Affairs · 9 transactions | — | 7.7Kas of Feb 2023 | 523.9K | — | 539.3K |
| Garcia Peter SChief Financial Officer · 3 transactions | — | 7.0Kas of Feb 2013 | — | 7.0K | — |
| Hernandez AlexandraSr Director Finance/Controller · 2 transactions | — | 6.0Kas of Mar 2021 | 6.0K | — | 6.0K |
| Gregg Valeta ADirector · 49 transactions | — | 5.7Kas of May 2010 | 74.0K | — | 74.0K |
| Leavitt Chase C.General Counsel/Secretary · 1 transaction | — | 5.0Kas of Aug 2019 | — | 5.0K | — |
| Roberts BrandiCFO & SVP, Finance · 1 transaction | — | 5.0Kas of Aug 2019 | — | 5.0K | — |
| Tew William P PHDChief Commercial Officer · 6 transactions | — | 3.3Kas of Jun 2014 | — | — | 43.9K |
| Von Eschenbach Andrew C.Director · 1 transaction | — | 3.0Kas of Aug 2013 | — | 3.0K | — |
| Berger Franklin MDirector · 1 transaction | — | 500as of Aug 2013 | — | 500 | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +26.97M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.